APixaban Versus PhenpRocoumon: Oral AntiCoagulation Plus Antiplatelet tHerapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation

Trial Profile

APixaban Versus PhenpRocoumon: Oral AntiCoagulation Plus Antiplatelet tHerapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Apixaban (Primary) ; Clopidogrel (Primary) ; Aspirin; Phenprocoumon
  • Indications Acute coronary syndromes; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms APPROACH; APPROACH-ACS-AF
  • Most Recent Events

    • 08 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 23 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top